PGEN PRECIGEN, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1356090 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY109.9%
TTM EPS YoY107.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin21.4%
Net margin15.6%
FCF margin-47.4%
EBITDA margin23.9%
Returns
ROE38.8%
ROA12.7%
ROIC (approx.)23.5%
Asset turnover0.82x
Leverage & solvency
Liabilities / assets60.5%
Debt / equity1.12x
Current ratio5.58x
Interest coverage2.85x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio50.9%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $9.68M | $3.92M |
| R&D expense | $41.33M | $53.07M |
| SG&A expense | $70.13M | $41.29M |
| Operating income | -$110.51M | -$135.03M |
| Interest expense | $3.87M | $6,000 |
| Pretax income | -$250.64M | -$128.03M |
| Income tax | $3,000 | -$1.79M |
| Net income | -$250.64M | -$126.23M |
| EBITDA | -$107.31M | -$130.50M |
| EPS (basic) | -1.37 | -0.47 |
| EPS (diluted) | -1.37 | -0.47 |
| Weighted avg. shares (diluted) | 312.98M | 267.73M |
| Balance sheet | ||
| Cash & equivalents | $30.23M | $29.52M |
| Short-term investments | $67.62M | $68.39M |
| Receivables | $3.92M | $926,000 |
| Inventory | $9.58M | $0 |
| Current assets | $115.23M | $102.41M |
| PP&E, net | $13.76M | $13.83M |
| Goodwill | $15.23M | $19.14M |
| Intangibles | $3.18M | $4.46M |
| Total assets | $155.50M | $145.27M |
| Current liabilities | $37.31M | $21.52M |
| Long-term debt | $93.17M | $0 |
| Total debt | $93.17M | $0 |
| Total liabilities | $134.59M | $78.53M |
| Shareholders' equity | $20.91M | $38.51M |
| Net debt | $62.94M | -$29.52M |
| Shares outstanding | 353.91M | 292.87M |
| Cash flow statement | ||
| Operating cash flow | -$87.83M | -$68.17M |
| Capital expenditure | $2.00M | $8.58M |
| Free cash flow | -$89.83M | -$76.76M |
| Investing cash flow | -$1.53M | -$20.71M |
| Financing cash flow | $90.05M | $110.58M |
| Depreciation & amortization | $3.20M | $4.53M |
| Stock-based compensation | $10.87M | $9.47M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.